Ingevity Corp (NGVT) earnings date, results and what the price requires
NYSE · SEC CIK 0001653477 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $314.1M | $35.3M | $1.00 | Filing |
| Mar 31, 2026 | May 6, 2026 | $258.0M | $59.8M | $1.66 | Filing |
| Dec 31, 2025 | Feb 25, 2026 | $255.1M | $-84.6M | $-2.33 | Filing |
| Sep 30, 2025 | Nov 5, 2025 | $333.1M | $43.5M | $1.18 | Filing |
| Jun 30, 2025 | Aug 4, 2025 | $331.5M | $-146.5M | $-4.02 | Filing |
| Mar 31, 2025 | May 5, 2025 | $247.9M | $20.5M | $0.56 | Filing |
| Dec 31, 2024 | Jan 16, 2025 | $135.6M | $16.6M | $0.44 | Filing |
| Sep 30, 2024 | Oct 29, 2024 | $333.8M | $-107.2M | $-2.94 | Filing |
What would Ingevity Corp have to report for its valuation to change?
At $70.54, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 31.9% a year, to $6.03. On that path the next quarter needs diluted EPS near $1.56, against $1.18 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 31.9% | 31.9% |
| EPS needed in final year | $6.03 | $6.03 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. NGVT goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.